Teneligliptin
Teneligliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the degradation of incretin hormones GLP-1 and GIP, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon release, and improving glycemic control in type 2 diabetes. Its unique thiazolidine-based structure provides prolonged DPP-4 inhibition and is approved in Japan, South Korea, and India for type 2 diabetes management. It may have additional cardiovascular benefits through reduction of myocardial remodeling, making it of interest in heart failure research.
Molekularmasse
426,6000 g/mol
LogP
2,40
TPSA
81,90 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Pharmacokinetics (PK)
Pharmacodynamics (PD)
2D-Struktur
Cite this structure
Embed this structure
SMILES
Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1
InChI
InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
Molecular Formula
C22H30N6OS
HBD / HBA
1 / 6
Rotierbare Bindungen
4
Schwere Atome
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Teneligliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the degradation of incretin hormones GLP-1 and GIP, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon release, and improving glycemic control in type 2 diabetes. Its unique thiazolidine-based structure provides prolonged DPP-4 inhibition and is approved in Japan, South Korea, and India for type 2 diabetes management. It may have additional cardiovascular benefits through reduction of myocardial remodeling, making it of interest in heart failure research.
Yes, Teneligliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2147777. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11949652. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="teneligliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/teneligliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/teneligliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/teneligliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="teneligliptin"></drugfyi-drug>